Literature DB >> 18764842

The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus.

A Wozniacka1, A Lesiak, J Boncela, K Smolarczyk, D P McCauliffe, A Sysa-Jedrzejowska.   

Abstract

BACKGROUND: There are very few data addressing the mechanisms of antimalarial treatment benefit locally within the skin of patients with lupus erythematosus, at the level of cytokine messenger RNA (mRNA) expression.
OBJECTIVES: The aim of this study was to evaluate whether 3 months of monotherapy with chloroquine influences the mRNA skin expression of interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha (TNF-alpha) in nonirradiated and locally ultraviolet B (UVB) irradiated nondiseased skin of patients with systemic lupus erythematosus (SLE). PATIENTS/
METHODS: Skin biopsies were collected from 14 patients with SLE 24 h after irradiation at one site and from an adjacent unirradiated site, before and after 3 months of chloroquine treatment. Messenger RNA levels for IL-1beta, IL-6 and TNF-alpha were determined by relative quantitative reverse transcriptase-polymerase chain reaction (RT-PCR).
RESULTS: There were no significant differences in the levels of mRNA cytokine expressions in the unirradiated sites before and after 3 months of chloroquine administration. In the irradiated sites, the expression of all three cytokine mRNA levels was significantly higher than in the unirradiated group, approximately 24 h after irradiation, before chloroquine treatment. Significantly lower expression of IL-1beta, IL-6 and TNF-alpha mRNAs was noted in irradiated skin samples after 3 months of chloroquine treatment.
CONCLUSIONS: These results demonstrate the local inhibitory effects of chloroquine on UVB-induced upregulation in the mRNA expression of proinflammatory cytokines in irradiated skin of SLE patients, and provide further insight into the apparent immunomodulatory, anti-inflammatory and photoprotective properties of chloroquine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18764842     DOI: 10.1111/j.1365-2133.2008.08804.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 2.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

Review 3.  Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article.

Authors:  Annamaria Mascolo; Pasquale Maria Berrino; Pietro Gareri; Alberto Castagna; Annalisa Capuano; Ciro Manzo; Liberato Berrino
Journal:  Inflammopharmacology       Date:  2018-06-09       Impact factor: 4.473

4.  Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop.

Authors:  Jasmine N Stannard; Tamra J Reed; Emily Myers; Lori Lowe; Mrinal K Sarkar; Xianying Xing; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Invest Dermatol       Date:  2016-09-16       Impact factor: 8.551

5.  Staphlyococcus aureus phenol-soluble modulins stimulate the release of proinflammatory cytokines from keratinocytes and are required for induction of skin inflammation.

Authors:  Adnan K Syed; Tamra J Reed; Kaitlyn L Clark; Blaise R Boles; J Michelle Kahlenberg
Journal:  Infect Immun       Date:  2015-06-15       Impact factor: 3.441

Review 6.  Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways.

Authors:  Lokman Varisli; Osman Cen; Spiros Vlahopoulos
Journal:  Immunology       Date:  2019-12-22       Impact factor: 7.397

7.  Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

Authors:  Janna Krueger; Francois Santinon; Alexandra Kazanova; Mark E Issa; Bruno Larrivee; Richard Kremer; Catalin Milhalcioiu; Christopher E Rudd
Journal:  PLoS One       Date:  2021-06-28       Impact factor: 3.240

8.  Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study.

Authors:  Isak Samuelsson; Ioannis Parodis; Iva Gunnarsson; Agneta Zickert; Claes Hofman-Bang; Håkan Wallén; Elisabet Svenungsson
Journal:  Lupus Sci Med       Date:  2021-07

Review 9.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650

10.  Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.

Authors:  Juliana Cruz da Silva; Henrique Ataide Mariz; Laurindo Ferreira da Rocha; Priscilla Stela Santana de Oliveira; Andrea Tavares Dantas; Angela Luzia Branco Pinto Duarte; Ivan da Rocha Pitta; Suely Lins Galdino; Maira Galdino da Rocha Pitta
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.